These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22124545)

  • 1. The rapid efficacy of abatacept in a patient with rheumatoid vasculitis.
    Fujii W; Kohno M; Ishino H; Nakabayashi A; Fujioka K; Kida T; Nagahara H; Murakami K; Nakamura K; Seno T; Yamamoto A; Kawahito Y
    Mod Rheumatol; 2012 Aug; 22(4):630-4. PubMed ID: 22124545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fusion protein abatacept. Remission in every 5th TNF-alpha refractory patient].
    MMW Fortschr Med; 2008 Jun; 150(26-27):56-7. PubMed ID: 18683309
    [No Abstract]   [Full Text] [Related]  

  • 3. Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments?
    Taylor PC
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):128-9. PubMed ID: 16932670
    [No Abstract]   [Full Text] [Related]  

  • 4. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
    Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M
    J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
    Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
    J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis].
    Harigai M
    Clin Calcium; 2007 Apr; 17(4):577-84. PubMed ID: 17404488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.
    Pincus T; Bergman MJ; Yazici Y; Hines P; Raghupathi K; Maclean R
    Rheumatology (Oxford); 2008 Mar; 47(3):345-9. PubMed ID: 18238788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CTLA4-Ig (abatacept)].
    Harigai M
    Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rheumatoid arthritis: strategies for biotherapy].
    Nau JY
    Rev Med Suisse; 2012 Oct; 8(358):1988-9. PubMed ID: 23198655
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis.
    Sumida K; Ubara Y; Takemoto F; Takaichi K
    Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S133. PubMed ID: 21385558
    [No Abstract]   [Full Text] [Related]  

  • 16. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
    Scheinfeld N
    J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory adult-onset still disease successfully treated with abatacept.
    Ostrowski RA; Tehrani R; Kadanoff R
    J Clin Rheumatol; 2011 Sep; 17(6):315-7. PubMed ID: 21869709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
    Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
    Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
    Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Horneff G; Huppertz HI; Job-Deslandre C; Loy A; Minden K; Punaro M; Nunez AF; Sigal LH; Block AJ; Nys M; Martini A; Giannini EH;
    Arthritis Rheum; 2010 Jun; 62(6):1792-802. PubMed ID: 20191582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale.
    Wells G; Li T; Tugwell P
    Ann Rheum Dis; 2010 Oct; 69(10):1768-73. PubMed ID: 20610444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.